Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia

Business Wire, Aug 8, 2018


AbbVie-Backed Startup Raises $133 Million To Fight Alzheimer's With Immunotherapy

Forbes, Jul 25, 2018


Bay Area biotech firm chases medicine’s white whale: Alzheimer’s cure

San Francisco Chronicle, Jul 25, 2018


In pursuit of Alzheimer's, cancer, growing Alector lands $133 million

San Francisco Business Times, Jul 25, 2018


A company that's taking a new approach to tackling Alzheimer's is moving into human trials after raising $133 million

Business Insider, Jul 25, 2018



BioCentury, Jul 25 2018


With a new HQ under construction and AbbVie as a partner, Alector grabs $133M round to fund a move into the clinic

Endpoints, Jul 25, 2018


Alector Snags $133M to Activate Immune Cells Against Neurodegeneration

Xconomy, Jul 25, 2018


Alector raises $133M in 5th VC round to push neuro-immunology drugs into Alzheimer’s trials

FierceBiotech, Jul 25, 2018


Alector, Staying Private for Now, Pulls in $133M for Alzheimer’s R&D

Timmerman Report, Jul 25, 2018


Term Sheet -- Wednesday, July 25

Fortune, Jul 25, 2018


Alector raises $133 million in Series E round for neurology drug development

MedCityNews, Jul 25, 2018


$133 million financing for Alector, which reveals targets of 3 drug candidates in Alzheimer's and FTD

The Pharma Letter, Jul 25, 2018


Alector Closes $133 Million to Expand Alzheimer’s Programs

Biospace, Jul 25, 2018


Alector all in on immuno-neurology; $133M series E to advance trio of assets to clinic

BioWorld Today, Jul 25, 2018


Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology Programs

Press Release, Jul 25, 2018


With new attack on Alzheimer's, this young biotech is hiring, grabbing more space

San Francisco Business Times, Jul 23, 2018


VC Bets on Blood, Immune Deals Signal New Medical Imperatives

WSJ Pro Private Equity, Mar 13, 2018


Alector to Present at Cowen and Company 38th Annual Health Care Conference

BusinessWire, Mar 8, 2018



Alector and AbbVie Announce Collaboration to Advance Immune Therapies for Patients with Alzheimer's Disease

PR Newswire, Oct 24, 2017


A company that's taking a new approach to tackling Alzheimer's just landed a $225 million endorsement

Business Insider, Oct 24, 2017


AbbVie antes up $225M in cash to buy into the Alzheimer’s platform at Alector

Endpoints News, Oct 24, 2017


Alzheimer's immunotherapy boosted by AbbVie deal

Financial Times, Oct 24, 2017


Could a New Immunotherapy Medical Approach Break the Alzheimer's Drug Curse?

Fortune, Oct 24, 2017


AbbVie Shells Out $205M Upfront for Alector's Antibodies Vs. Alzheimer's

Timmerman Report, Oct 24, 2017


AbbVie bets on Alzheimer's immunotherapy with big biotech deal

Reuters, Oct 24, 2017


AbbVie, Alector pair for Alzheimer’s in $205M pact

FierceBiotech, Oct 24, 2017


With new approach to Alzheimer's, Peninsula company seals $225M deal with drug giant AbbVie

San Francisco Business Times, Oct 24, 2017


AbbVie invests in Alector’s immunoneurology therapies for Alzheimer’s

Chemical and Engineering News, Oct 24, 2017


Full-court Press by Alector: Neuro-immunology effort draws $205M from AbbVie

BioWorld, Oct 25, 2017



The Road Less Traveled: Start-ups invest in novel approaches against neurodegeneration.

Nature Medicine, 22, 11-13 (2016)


Dementia Discovery Fund Chooses Alector for First Investment

Wall Street Journal, Jan 7, 2016



Fierce Biotech’s 2015 Fierce 15



Google, OrbiMed buy into Alector’s novel take on Alzheimer’s with a $32M round

FierceBiotech, Sept 16, 2015


Alector Raises $32M for Immune-Based Neuro Drug Development

Xconomy, Sept 16, 2015



Top 30 Life Science Startups to Watch in the US

BioSpace, Oct 23, 2014



‘Alector’ See Alzheimer’s Beat: Series A to Fund Antibody Bid

BioWorld Today, Nov 1, 2013


The Daily Startup: Alector Seeks Cure for Alzheimer’s Disease

Wall Street Journal, Oct 31, 2013


Alector snags funding in founder’s latest attack on Alzheimer’s

San Francisco Business Times, Oct 31, 2013


Alector Goes After Alzheimer’s, With Cash from Polaris and OrbiMed

Xconomy, Oct 31, 2013


Alzheimer’s experts team up with Adimab, grab $10M to launch Alector

FierceBiotech, Oct 30, 2013